$DNTH insider trading
Over the last 12 months, Dianthus Therapeutics insiders reported no purchases and 22 sales totaling $69.9M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $69.9M 22 events
- Events · 12m
- 22 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 100% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 23,124 | $106.41 | $2.5M | -85.3% | plan · 3 tranches |
| Aug 19, 2026 | Read SimonD | ▼ Sale | 2,778 | $117.55 | $327K | -100% | plan |
| Aug 10, 2026 | McGeorge AnneD | ▼ Sale | 7,750 | $109.01 | $845K | -100% | plan · 5 tranches |
| Aug 10, 2026 | Read SimonD | ▼ Sale | 2,777 | $109.55 | $304K | -100% | plan · 6 tranches |
| Aug 10, 2026 | Veness Adam MSVP, General Counsel and Sec. · O | ▼ Sale | 20,000 | $110.44 | $2.2M | -100% | plan · 3 tranches |
| Aug 7, 2026 | Garcia MarinoCEO AND PRESIDENT · O·D | ▼ Sale | 166,000 | $108.11 | $17.9M | -71.8% | plan · 7 tranches |
| Jul 9, 2026 | Savitz RyanEVP, CFO & CBO · O | ▼ Sale | 31,249 | $101.03 | $3.2M | -100% | plan · 3 tranches |
| Jun 17, 2026 | Veness Adam MSVP, General Counsel and Sec. · O | ▼ Sale | 30,000 | $80.8 | $2.4M | -100% | plan · 2 tranches |
| Jun 1, 2026 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 4,159 | $91.37 | $380K | -51% | plan |
| Jun 1, 2026 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 16,943 | $90.72 | $1.5M | -67.5% | plan |
| Jun 1, 2026 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 5,428 | $89.72 | $487K | -17.8% | plan |
| May 8, 2026 | Soteropoulos PaulaD | ▼ Sale | 599 | $85.47 | $51K | -100% | plan |
| Apr 9, 2026 | Savitz RyanEVP, CFO & CBO · O | ▼ Sale | 8,224 | $89.84 | $739K | -100% | plan |
| Mar 31, 2026 | Savitz RyanEVP, CFO & CBO · O | ▼ Sale | 114,367 | $83 | $9.5M | -100% | plan · 8 tranches |
| Mar 31, 2026 | Soteropoulos PaulaD | ▼ Sale | 599 | $80.11 | $48K | -100% | plan |
| Mar 24, 2026 | Soteropoulos PaulaD | ▼ Sale | 27,594 | $78.05 | $2.2M | -100% | plan |
| Mar 12, 2026 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 33,830 | $81.48 | $2.8M | -100% | plan |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT · O·D | ▼ Sale | 122,918 | $81.49 | $10.0M | -100% | plan · 5 tranches |
| Mar 12, 2026 | CARR EDWARDCHIEF ACCOUNTING OFFICER · O | ▼ Sale | 43,682 | $81.49 | $3.6M | -100% | plan · 5 tranches |
| Dec 4, 2025 | Savitz RyanCFO & CBO · O | ▼ Sale | 20,000 | $45.18 | $904K | -100% | plan |
| Nov 14, 2025 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 196,538 | $37.55 | $7.4M | -98% | plan · 4 tranches |
| Sep 9, 2025 | Savitz RyanCFO & CBO · O | ▼ Sale | 20,000 | $35 | $700K | -100% | plan |
Every $DNTH filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Dianthus Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $DNTH feed.